Report on the risk assessment of N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances
Introduction
This publication presents the data and findings of the risk assessment on N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 25 September 2017, the Council decided that acryloylfentanyl should be subject to control measures across the Member States.
Download as PDF
Table of contents
- Foreword
- EMCDDA actions on monitoring and responding to new drugs
- EMCDDA–Europol Joint Report on acryloylfentanyl: a summary
- Risk Assessment Report of a new psychoactive substance: acryloylfentanyl
- Annex 1: Technical report on acryloylfentanyl
- Council Decision on subjecting acryloylfentanyl to control measures
- Participants of the risk assessment meeting